Investigating the effects of prenatal dolutegravir exposure on child development
Evaluating timing and extent of prenatal exposure to dolutegravir and early childhood outcomes
This study is looking at how being exposed to the HIV medicine dolutegravir before birth affects the brain development of babies born to moms with HIV, and it’s for families in Kenya to help understand how this treatment might impact their children's growth.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10381035 on NIH RePORTER |
What this research studies
This research evaluates how prenatal exposure to the antiretroviral drug dolutegravir affects the neurodevelopment of children born to mothers living with HIV. The study focuses on comparing the developmental outcomes of infants who were exposed to both HIV and antiretroviral therapy with those who were only exposed to antiretroviral therapy. By assessing a large group of infants in Kenya, the research aims to gather important safety data and understand the long-term impacts of this treatment on child development.
Who could benefit from this research
Good fit: Ideal candidates for this research include pregnant women living with HIV who are receiving dolutegravir as part of their treatment regimen.
Not a fit: Patients who are not pregnant or those who are not living with HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved guidelines for the use of dolutegravir in pregnant women, ultimately enhancing the health outcomes of their children.
How similar studies have performed: Previous studies have shown promising results regarding the safety of dolutegravir, but this research aims to provide novel insights into its long-term effects on child neurodevelopment.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Pintye, Jillian — University of Washington
- Study coordinator: Pintye, Jillian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.